Previous investigations have found that increasing circulating glucose availability can increase memory performance in rodents, healthy humans, and individuals with dementia of the Alzheimer's type. In this study, patients with schizophrenia, healthy control subjects, and controls with bipolar affective disorder were tested using double-blind treatment with either 50 g anhydrous dextrose plus 4 mg sodium saccharin (for "taste") or 23.7 mg saccharin alone, followed by cognitive testing on a complex battery. At this glucose dose, verbal memory performance on a paragraph recall task was increased during the glucose condition relative to the saccharin condition in the patients with schizophrenia; this effect was not detected hi either the psychiatric or normal controls. The results provide preliminary support for the hypothesis that memory performance can be improved in patients with schizophrenia by increasing circulating glucose availability and suggest the importance of further evaluation of therapeutic manipulations of glucose availability.
Schizophrenia is a neuropsychiatric disorder associated with a variety of cognitive deficits, including prominent impairments in learning and memory performance (Gruzelier et al. 1988; Saykin et al. 1991) . The capacity to learn and recall facts and events over short intervals has been strongly linked to a medial-temporal lobe declarative memory system comprised of the hippocampus and adjacent entorhinal, parahippocampal, and perirhinal cortices (Squire et al. 1992) . There is currently a limited understanding of the neurophysiology and neuropharmacology of memory performance impairments in schizophrenia, and this is reflected in the lack of specific treatments for cognitive impairment in schizophrenia (Goldberg and Weinberger 1996) . Unfortunately, cognitive impairments, especially memory and learning impairments, are strongly related to poorer functional outcomes in schizophrenia, including poorer skill acquisition, social problem solving, and community outcomes (Green 1996) . The principal energy substrate for the brain is glucose and its metabolic products (e.g., lactate) (Friedman and Goldman-Rakic 1988; Satar et al. 1989; Friedman et al. 1990; Sif et al. 1991; Tsacopoulos and Magistretti 19%) . In vivo experiments using 'H-magnetic resonance spectroscopy ('H-MRS; Prichard et al. 1991; Sappey-Marinier et al. 1992 ) and positron emission tomography (PET; Fox and Raichle 1986; Fox et al. 1988 ) have demonstrated glycolysis and lactate production during neuronal activation in humans. Alterations in glucose availability can effect neuronal function, including cognitive performance. Several groups, but not all (e.g., Gur et al. 1995) , have reported reductions in either regional cerebral blood flow (Kawasaki et al. 1993) or glucose metabolic rate in the medial-temporal lobe/hippocampus of patients with schizophrenia (Tamminga et al. 1992; Siegel et al. 1993) . However, the pathophysiology underlying these findings has not been established.
Increases in memory performance have been reported during experimental increases in circulating glucose levels in older rodents, healthy younger and older adult humans, and individuals with dementia of the Alzheimer's type (Gonder-Frederick et al. 1987; Gold and Stone 1988; Hall et al. 1989; Manning et al. 1990 Manning et al. , 1992 Craft et al. 1992 Craft et al. , 1993 . Investigators have also-reported that peripheral-injections-of-glucose in mice can attenuate memory deficits induced by both scopolamine (a muscarinic acetylcholine receptor antagonist) (Messier et al. 1990 ) and NPC 12626 (an tf-methyl-D-aspartate [NMDA] glutamate receptor antagonist) (Walker and Gold 1992) . The magnitude of glucose-induced memory improvements in humans is comparable to that produced by better established memory-improving agents (Davis et al. 1979; Drachman and Sahakian 1980) . These results suggest that strategies to increase neuronal glucose availability may offer novel targets for the development of cognition-enhancing treatments. Promising experimental results using increased glucose availability to improve cognitive performance in other study populations motivated this initial study of the cognitive effects of controlled hyperglycemia in patients with schizophrenia.
This experiment sought to evaluate the cognitive effects of placebo-controlled, fixed-dose glucose administration in patients with schizophrenia, as well as psychiatric controls with bipolar affective disorder (BAD) and normal control subjects. The experiment used an oral dextrose dose previously associated with declarative memory performance facilitation in patients with dementia of the Alzheimer's type (Craft et al. 1992 (Craft et al. , 1993 . The primary study hypothesis was that patients with schizophrenia would demonstrate increases in declarative memory performance during glucose treatment relative to their performance during a control (placebo) condition. The secondary hypotheses were that the cognitive effect of increasing circulating glucose availability would be preferential for declarative memory performance versus other differentiated elements of cognitive performance, and that memory facilitation effects at this fixed dose would vary across subject groups analogous to previous reports (i.e., facilitation in Alzheimer's subjects but not in healthy controls).
Methods
Subjects. Thirty-one adult subjects participated after giving written informed consent. The study was approved by the Human Studies Committee at Washington University School of Medicine and the Professional Review Committee of the Department of Mental Health for Missouri. Patients with schizophrenia (n = 10) and bipolar disorder (n = 10) were recruited through Malcolm Bliss Mental Health Center (MBMHC), a State-supported acute-care psychiatric facility. Preliminary research eligibility, including consensus Clinical Global Impression (CGI; Guy 1976) ratings (see below), was determined in a twice weekly research meeting. Normal controls (n = 11) were recruited from the local community through advertising. Subjects were selected for study entry following a medical screening interview and a diagnostic evaluation that included a structured diagnostic interview using the Diagnostic Interview for Genetic Studies (DIGS; Numberger et al. 1994 ) and a review of all available medical records. The final research diagnosis was made by a psychiatrist (J.W.N.) or a psychologist (S.O.M.) using DSM-III-R (American Psychiatric Association 1987) algorithms. Subjects were excluded for Axis I disorders except those studied and for substance abuse and/or dependence occurring less than 6 months prior to study entry. Subjects also were excluded for medical conditions that could confound cognitive or glucoregulatory assessments. These included any history of insulin-or noninsulin-dependent diabetes mellitus, cardiovascular conditions causing clinically recognized hemodynamic compromise, respiratory conditions causing clinically recognized hypoxia, malignancy, epilepsy, endocrine disease (with the exception of historical thyroid abnormalities with currently clinically stabilized and corrected indices of thyroid function), current fever, dehydration, nausea, body weight < 80 percent ideal body weight, pregnancy or high dose estrogen therapy, narcotic therapy, sedative hypnotic withdrawal, corticosteroid or spironolactone therapy, or any changes in cognitively active (e.g., psychoactive) medications within 10 days of the baseline study session. A single normal control subject was excluded from the analysis and referred for medical follow-up because of post-dextrose plasma insulin levels 10 standard deviations above the mean for the other subjects.
Patients were studied either in the final days of hospitalization or soon after discharge, and were specifically required to meet operational criteria for "clinical stability" prior to study entry: Inpatients had to have unchanged weekly CGI "severity of illness" scores for 1 week if their CGI scores were 1 to 3, for 3 successive weeks for a CGI score of 4, and for 5 successive weeks for a CGI score of 5 or more; a small number of outpatients without post-discharge CGIs had to demonstrate clinical stability for at least 90 days without a greater than 10 percent increase in antipsychotic or antimanic medication.
Seven of the 10 patients with schizophrenia were receiving haloperidol (mean daily dose ± SD = 19.0 mg ± 8.8). Four of these subjects were also receiving benztropine mesylate (mean daily dose = 2.75 mg ± 3.2), one was receiving adjunctive lithium carbonate (600 mg/day), and one was receiving adjunctive lorazepam (1.5 mg/ day). Three of the 10 patients with schizophrenia were receiving clozapine (mean daily dose = 633.3 mg ± 251.7). Within the BAD group, 6 of the 10 patients were receiving lithium carbonate (mean daily dose = 1450.0 mg ± 350.7), 3 were receiving carbamazepine (mean daily dose = 333.3 mg ± 230.9), 1 was receiving paroxetine (30 mg/day), 1 sertraline (100 mg/day), and 1 adjunctive lorazepam (0.5 mg/day). At the time of study, 6 of the 10 patients with BAD were also receiving "typical" neuroleptic medication (haloperidol [n = 4], fluphenazine [n = 1], thiothixene [n = 1]; mean daily dose = 7.3 mg ± 2.5 in haloperidol equivalents); of these, 4 were also taking benztropine mesylate (mean daily dose = 2.25 mg ± 0.5). Baseline clinical data for subjects is shown in table 1.
Control groups were matched to parental rather than patient's years of education or occupation in order to avoid inappropriately underachieving control groups (Meehl 1970 (Oldfield 1971) within approximately 1 week of baseline.
Procedure. On the morning following a baseline (practice) cognitive test session, subjects in each diagnostic gTOup received counterbalanced, double-blind (subject and cognitive tester) assignment to either a dextrose-or sodium-sacxharm-containing beverage. On the next and final study morning they were assigned to the alternate beverage. Testing followed an overnight fast of at least 9 hours. At approximately 8:00 AM on each of the two mornings, subjects had an intravenous (IV) catheter placed for blood sampling. Subjects consumed a 453.5 g (16 oz) orange-flavored beverage sweetened with either 23.7 mg sodium saccharin or 50 g anhydrous dextrose powder. Four mg of sodium saccharin were added to the dextrose beverage to make taste comparable. Blood glucose concentration was acutely monitored using an Accutest II (Lifescan, Johnson & Johnson) . On each study day, subjects had baseline, 15-, 45-, and 75-min postingestion blood sampling and began cognitive testing 15 min after beverage ingestion.
Cognitive Assessment. All of the cognitive measures were constructed or modified so that multiple versions are available for use in repeated measures study designs. Different versions of each of the tasks, matched for difficulty, were administered on each study day. Different versions of the 90-min cognitive battery were given at each session, and two different sets of these alternate versions were counterbalanced across subject and treatment groups (i.e., alternating the battery set for each successive patient with schizophrenia who was assigned to receive glucose first), in order to minimize the effects of practice and any response bias. The battery consisted of measures of mem- ory performance and other differentiated elements of cognitive performance as a control for the selectivity of treatment effects and was given in the order that follows.
1. A paragraph recall test (Wechsler 1945 ) was used as a validated (Squire 1987 ) and sensitive measure (Butters et al. 1978; Storandt et al. 1984 ) of verbal declarative memory performance. Although performance also depends on intact organizational and learning strategies and on the functioning of odier brain structures, paragraph recall has been strongly related to the integrity of a medial-temporal lobe declarative memory system that includes hippocampus (Squire et al. 1992 ). Subjects hear a recorded narrative with 25 bits of information, modeled on the Wechsler Memory Scale-Revised Logical Memory Test (Wechsler 1987) , followed by immediate and delayed (20 min) recall. Paragraphs were constructed using an established method (Wechsler 1987) , and the reliability of performance across individual paragraphs was previously established . Two paragraphs are given each session, and scores for correct recall are tabulated using established methods (Gangarosa et al. 1988) . Total scores for correct verbatim recall are tabulated for both immediate and delayed conditions. In addition, a retention score (delayed recall score/immediate recall score) is calculated in order to measure retention from immediate to delayed trials, a function previously associated with medial-temporal lobe functioning (Lencz et al. 1992) . When delayed recall score exceeded immediate score for a small number of individual paragraphs, that paragraph (but not the other for that study day) was excluded from the analysis of retention only, in order to preserve a conservative and observable measure of retention. Two normal subjects whose retention scores were greater than 1 on both paragraphs on one study day were excluded from the retention analysis only.
2. A multiple version modification of Raven's Colored Progressive Matrices (Raven 1936 (Raven , 1965 ) was utilized to measure nonverbal problem solving and abstract reasoning via visual analogy (Lezak 1983; Spreen and Strauss 1991) . Performance on the original version of this task has been associated with primarily posterior (parieto-occipital) brain function in controls and persons with schizophrenia (Berman et al. 1988) . Multiple versions of six items each were constructed by selecting items from the Raven's Colored Progressive Matrices and matching sets for overall difficulty level. The total number of correct responses was included in the analysis.
3. The integrity of visuoperceptual function was assessed using a multiple version modification of the Benton Judgment of Line Orientation task (Benton et al. 1983) with errors scored as the number of incorrectly identified lines. 4. A multiple version modification of the Stroop color-word interference task (Stroop 1935 ) was used as a measure of selective attention. This task has also been shown to be sensitive to frontal lobe dysfunction, requiring effortful, on-line processing (Perret 1974) . The total time to complete each condition and the number of incorrect responses per condition were included in the analysis. (Delayed paragraph recall follows this task.) 5. A word-list learning task using unrelated words, based loosely on the California Verbal Learning Test (Delis et al. 1991) , was employed as another measure of verbal declarative memory performance. In this task, subjects listened to a list of 12 words and were asked to recall as many as possible, in any order; this procedure was performed three times in all. Subjects then heard and were asked to recall a second 12-word list. Immediately after recalling the second-interference-list, subjects were asked to recall the first list. Free recall for the first list and recognition were measured after a 15-min delay. Words were randomly chosen nouns with Kucera and Francis (1967) frequency greater than 20, Thorndike and Lorge (1963) familiarity, concreteness and imagery ratings over 500, and a word length of four to six letters. Words were randomly assigned to groups mat were then balanced for mean Kucera-Francis frequency and word length. Distractor words on the recognition trial were matched on the variables listed. Total recall from immediate and delayed recall conditions were used in the analysis.
6. An auditory vigilance task (Weintraub and Mesulam 1985) , requiring sustained attention and working knowledge of the alphabet, involved a standardized audiotape presentation from which subjects were asked to identify the letters of the alphabet, in sequence, as each one was heard during a random series of letters. An error score was constructed for use in the analysis. (Delayed list recall followed this task.) 7. A pattern recall and recognition task was used as a spatial declarative memory task (Craft et al. 1992) . A total of three immediate recall trials were given, each consisting of three 3x3 checkerboard grids with four squares filled for each grid. Free recall for each of the patterns was then tested after a 15-min delay. Subjects received one point for each blackened section correctly reproduced. Following delayed recall, subjects were asked to recognize the three test patterns versus nine distractor patterns.
8. Word-stem priming and memory tasks were used to assess both priming and declarative memory performance in a previously described, four-task, computerized assessment (Squire et al. 1992) . Priming was used as a control for changes in a nondeclarative memory function. Participants were required first to simply pronounce a list of 15 words presented on a computer screen and judge each one on "familiarity" and "liking." A 5-point scale was used (from "very unfamiliar" or "dislike very much" to "very familiar" or "like very much"). The presentation rate was controlled at 4 sec per word. Participants were not told to study or memorize the words. After two repetitions of the list, there was a 3-min distraction period. Then participants were shown a list of 20 three-letter word stems that had to be completed as quickly as possible to form a common English word (e.g., "STA" could be completed as stand, stare, etc.). Half of the stems could be completed to form one of the words from the original list (priming). The other half of the stems could be completed to form words not viewed previously in this task (baseline). All words were equivalent in frequency and all stems could be completed with at least 10 common English words. One of the 10 possible word completions for each of these 20 stems was randomly chosen as the correct word completion. Half of these chosen words were used for priming and the other half were not presented. Immediately following the word-stem completion task, participants were asked to recall as many of the words that they had seen on the computer screen and had rated for familiarity and liking (total =15). This task was added in order to measure declarative recall for the words presented. The total number of correct words recalled in the memory and priming conditions was used in the analysis.
9. A multiple version modification of a Paced Serial Addition Test (Gronwell and Wrightson 1974) was used to measure sustained attention and working memory. The task involved standardized audiotape presentation of sets of number strings that subjects were asked to add up. Errors were recorded for use in the analysis. (Word-stem priming recall followed this task.) 10. A word list generation (verbal fluency) task was used as a measure of prefrontal cortical function (Milner 1964) . Poor performance on this task has been found in some patients with schizophrenia (Barr et al. 1989) . Correct responses were scored on two trials for each treatment condition, using a different letter for each trial. The total number of correct responses was used in the analysis. (Delayed pattern recalrfollowed this task.) 11. A modified version of the Wisconsin Card Sort Task (WCST) was administered following the procedures of Goldberg et al. (1987) . This test represents an assessment of abstract thinking and has been used to measure the capacity of subjects to shift their attentional focus and attain new concept formation (Grant and Berg 1948) . Stimuli order for "shape," "color," and "number" was varied to produce multiple versions that were used on different study days; on each study day, stimuli were presented in their fixed order twice. Only the number of categories achieved was used in the analysis, for the purpose of data reduction.
Plasma Assays. Assays were performed through the laboratory of the General Clinical Research Center at Washington University School of Medicine. Plasma glucose concentrations were measured by the glucose oxidase method using a glucose analyzer (Beckman Instruments, Fullerton, CA). Plasma insulin (Kuzuya et al. 1977) and cortisol (Farmer and Pierce 1974) concentrations were measured by radioimmunoassay.
Data Analysis. The primary study hypothesis was that fixed dose glucose treatment would increase memory performance in patients with schizophrenia. This was tested using a mixed design analysis of variance (ANOVA) within that subject group, with one within-subjects repeated measure (treatment condition) and one betweensubjects factor (order of treatment conditions [e.g., dextrose first]). This analysis assessed free-recall measures from the paragraph recall (verbatim), list learning, and pattern recall tasks and the memory component of the word-stem priming/memory task. An additional withinsubjects factor, recall condition (e.g., immediate versus delayed), was added for the assessment of paragraph recall, pattern recall, and list learning measures. The secondary hypothesis-that the cognitive response to glucose would vary across subject groups-was tested using a mixed design ANOVA, with one within-subjects repeated measure (treatment condition), and two between-subjects factors (order of treatment conditions and diagnostic group). Again, an additional within-subjects factor, recall condition, was added for the assessment of appropriate measures. Otherwise identical analyses of the other "control" cognitive measures in the experiment were performed in order to address the secondary hypothesis concerning the specificity of treatment effects on declarative memory versus other elements of cognitive performance. The comparability of plasma conditions achieved across the subject groups in response to the fixed-dose treatment was explored in a mixed design ANOVA that tested treatment condition X diagnostic group X plasma sample time. In all cases, significant effects were further defined by appropriate contrast analyses.
Results
Cognitive Results. The ANOVA that tested the primary hypothesis for paragraph recall performance in the patients with schizophrenia detected a main effect of recall condition (F[l,8] = 29.77, p -0.0006) and an interaction between recall condition and treatment condition (F[l,8] = 6.38, p = 0.036). Respectively, these indicated expected overall differences between immediate and delayed recall performance and a differential treatment effect across recall conditions. In testing the effect of treatment condition on individual recall conditions of paragraph performance in the patients with schizophrenia, we found that performance on the delayed recall condition of the paragraph recall task was significantly increased during the hyperglycemic treatment relative to the saccharin condition (F[l,8] = 11.81, p = 0.009) (figure 1). This effect was not confounded by a significant main effect of, or interaction with, the order of treatment conditions. No significant effect of treatment condition was detected on immediate paragraph recall for the patients with schizophrenia (F[ 1,8] = 0.11, p = 0.75); nor was a significant effect of treatment condition or an interaction between treatment condition and recall condition, detected in the ANOVAs for the other three memory tasks (i.e., word list recall, pattern recall, word-stem priming recall). With respect to the possibility of an alpha error, the effect of treatment condition on delayed paragraph recall remained statistically significant after a Bonferroni correction for five statistical tests (i.e., ANOVAs for immediate and delayed paragraph recall, word list recall, pattern recall, and word-stem priming recall) used to test the primary hypothesis (p -0.045). Data from individual subjects showed that 9 out of 10 patients with schizophrenia demonstrated a glucose-induced increase in delayed recall performance (a single subject had a slight decline) relative to the saccharin control condition. Testing the secondary hypothesis concerning the selectivity of memory facilitation at this dose for the patients with schizophrenia, the mixed design ANOVA for paragraph recall detected main effects of diagnostic group (F[2,25] = 18.66, p = 0.0001) and recall condition (F[l,25] = 59.02, p = 0.0001), no significant interaction between group and treatment condition, and a significant interaction between recall condition and treatment condition (FT 1,25] = 5.02, p = 0.034). Guided by the result for schizophrenia patients on delayed paragraph recall, but without the benefit of a group X treatment interaction, we elected to test the effect of treatment condition on individual recall conditions of paragraph performance within each diagnostic group. While performance on the delayed recall condition of the paragraph recall task was significantly increased during the hyperglycemic treatment relative to the saccharin condition in patients with schizophrenia (described above), this was not the case in patients with BAD ( In brief, relatively lower immediate recall performance on glucose improved on a subsequent saccharin condition, while relatively higher performance on saccharin showed little change on a subsequent glucose condition (table 2) .
The difference in the treatment effect on immediate versus delayed recall performance was further defined by the analysis of retention scores on the paragraph recall task. Retention scores measured the degree of information retained from immediate to delayed recall trials. A mixed design ANOVA that examined paragraph retention detected significant interactions between treatment condition and diagnostic group (F [2, 22] 41.7 ±5.9 1.5 ± 1.9 1.7 ±1.6 27.6 ± 6.0 5.1 12.0 nificant main effect of, or interaction with, the order of treatment conditions. As with the raw paragraph recall data from which the retention measure was derived, this result remained statistically significant after a Bonferroni correction for the five tasks used to test the hypothesis (p = 0.035).
A modest tendency of hyperglycemia to improve performance on the general measure of visuoperceptual integrity, the Benton Judgment of Line Orientation task, was detected for normal subjects ( Consistent with a normal diurnal pattern, plasma cortisol levels fell during the mornings of the experiment for all groups independent of treatment condition, as indicated by a significant main effect of plasma sampling time only (F[3,45] = 28.67, p = 0.0001). No glucose-induced treatment effect on plasma cortisol was detected and no relationship with memory performance was found.
Discussion
Significance of Possible Glucose Effects on Memory Performance in Schizophrenia. Previous investigations have detected increases in memory performance during experimental increases in circulating glucose levels in rodents, healthy younger and older adults, and individuals with dementia of the Alzheimer's type (GonderFrederick et al. 1987; Gold and Stone 1988; Hall et al. 1989; Manning et al. 1990 Manning et al. , 1992 Craft et al. 1992 Craft et al. , 1993 in patients with schizophrenia, placebo-controlled, fixeddose oral dextrose (50 g) administration produced an increase in delayed paragraph recall performance; 9 of 10 individual patients demonstrated a glucose-induced increase in performance. The magnitude of the increase in performance in these young adult patients was similar to that seen in previous reports in other subject populations, and comparable to that achieved with better established memory-improving agents (Davis et al. 1979; Drachman and Sahakian 1980) . However, this initial report using a small subject sample should be interpreted with caution. Unlike consistent reports in other subject populations using a paragraph recall measure, the improvement in performance for the patients with schizophrenia in this study was detected only in the delayed recall condition. Notably, patients with schizophrenia characteristically demonstrate deficits in the encoding rather than the retrieval component of declarative memory (Koh 1978; Niederehe and Rusin 1987) . The restriction of the current results in patients with schizophrenia to an effect on retrieval, in contrast to consistent results in previous studies of healthy human subjects and patients with dementia of the Alzheimer's type, suggests that the neurobiology of this encoding defect might prevent glucose effects on all but the retrieval component of performance.
Glucose treatment increased paragraph recall performance but not performance on the other memory tasks or, in general, performance on tasks measuring other differentiated elements of cognitive performance. This is similar to previous reports detecting glucose-induced increases in declarative memory performance on the highly sensitive paragraph recall task (Craft et al. 1992 (Craft et al. , 1993 , where glucose did not increase performance on either list-learning tasks or the repeated memory trials of a pattern recall task. Because the list-learning and pattern recall tasks used in this study also have a major declarative memory component, some other aspect of these tasks is hypothesized to obscure glucose effects. The wordlist-based tasks and the pattern recall task share the characteristic of stimuli repetition over several trials, which previously has been suggested to create repetition priming effects that may predominate in determining recall under immediate and short-delay testing conditions (Craft et al. 1992 (Craft et al. , 1993 . Notably, Hall et al. (1989) reported a glucose-induced increase in performance on a paired associates task where associates were repeated over trials with recall tested after 24 hours, a period over which repetition priming effects are likely to dissipate. Similarly, Manning et al. (1990) reported a glucose-induced increase in memory for words that had not been repeated immediately prior to recall on a selective reminding task. Perhaps more importantly, glucose may have preferential effects on declarative memory performance and the paragraph recall task may simply be a more sensitive measure of change for this element of performance.
Some investigations in humans have detected glucose-induced improvements in attention (Craft et al. 1992; Benton et al. 1994) , and the current experiment detected modest improvement in the performance of control subjects on a measure of visuoperceptual integrity. Nevertheless, nonmemory effects have not been consistently described. Tn this experiment, as in previous studies in healthy subjects and patients with dementia of the Alzheimer's type, glucose administration did not increase performance on a difficult test of sustained attention and working memory (Paced Serial Addition Test). This finding suggests that glucose effects on paragraph recall may not simply be due to task difficulty. As in previous reports, no effect of glucose was detected for verbal fluency, another on-line task impaired by frontal lesions, and no effect was detected for a modified version of the WCST. These results suggest that reported glucose effects may not be due to a generalized facilitation of cognitive processing. Peak plasma glucose concentrations were achieved quickly after the oral load, followed by decreasing glucose levels throughout the rest of the cognitive battery. This suggests that performance on some measures may not have been sampled during exposure to sufficient glucose levels. However, the modified Raven, Benton Line Orientation, and Stroop tasks all were administered prior to the delayed paragraph recall condition, which indicates that not all of the negative results may be explained by reductions in glucose levels below an effective level. Future studies of glucose effects on differentiated elements of cognitive performance using oral loading should utilize shorter cognitive batteries to minimize differences in plasma conditions across cognitive tasks. Alternatively, experiments can be done with fixed plasma glucose and insulin concentrations using hyperglycemic and/or hyperinsulinemic intravenous "clamping" procedures (DeFronzo et al. 1979; Berk et al. 1985; Craft et al. 1993 Craft et al. , 1996a .
The oral fixed-dose glucose-induced increase in memory performance appeared to be selective for the patients with schizophrenia. However, these results should also be interpreted with caution given the small sample size and the lack of a significant interaction between diagnostic group and treatment condition in the ANOVA that evaluated this secondary hypothesis. Several alternative explanations and potential confounds should be considered, including the possibility that controls may have already been performing at the upper limit of their capacity. The lack of effect in both the BAD and healthy control groups does suggest that simply the effect of recent hospitalization, severity of illness^ or nonspecific effects of overall treatment with psychotropic medication may not explain the finding for patients with schizophrenia. Potential differences in specific medications received across the two patient groups are more difficult to evaluate. All of the patients with schizophrenia and most with BAD were on high potency "typical" neuroleptics except for several schizophrenia subjects on clozapine, whose results were not distinguished from those on haloperidol. Four subjects in each patient group were receiving adjunctive anticholinergic medications; a 20 percent higher dose in the patients with schizophrenia suggests the possibility that the improvement in performance seen in the patients with schizophrenia could have been due to an attenuation of anticholinergic effects by glucose (Messier et al. 1990 ). However, glucose-induced increases in performance were also detected in haloperidol-treated patients not receiving adjunctive anticholinergics. A single subject in each patient group was receiving adjunctive lorazepam, again at dissimilar doses, but without dissimilar results from the rest of the group. The single schizo-phrenia subject on lithium also experienced a glucoseinduced increase in recall performance. The potential confounding effects of medications would best be addressed in future studies of medication free patients. The selectivity of the memory performance increase for patients with schizophrenia using a fixed dextrose dose (50 g) is consistent with previous reports of memory facilitation in patients with dementia of the Alzheimer's type and not controls (Craft et al. 1992; Manning et al. 1992; Benton and Owens 1993) , and with the finding from intravenous infusion experiments that patient populations may require different plasma glucose and/or insulin levels than healthy subjects to produce memory facilitation (Craft et al. 1993 (Craft et al. , 1996a .
Another potential confound to the interpretation of differences in cognitive results across subject groups involves group differences in plasma conditions. While the cognitive measurement detecting memory facilitation in patients with schizophrenia took place during a postdose interval where plasma glucose and insulin measurements did not statistically differ across subject groups, both control groups fell short of the 150 mg/dl peak glucose level typically associated with memory facilitation in past reports. Past reports and the current results indicate that patients with schizophrenia may have differences from control groups in their peripheral response to glucose and insulin challenges (Braceland et al. 1945; Martin and Alford 1970; Brambilla et al. 1976) . Fixed plasma glucose and insulin concentrations, using hyperglycemic and/or hyperinsulinemic intravenous "clamping" procedures should be used in future studies so that differences in peripheral glucoregulation can be controlled, and disease-related differences in brain response to varying plasma glucose and insulin concentrations can be studied.
Physiology of Glucose-Induced Memory Improvement: Future Directions for Hypothesis Testing. Physiological mechanisms that explain glucose-induced increases in memory performance remain to be defined. Previous clinical and preclinical reports suggest a role for factors that affect glucose transport and intracellular availability. Hypoglycemia (Hirsch et al. 1991 ) and treatment with glucocorticoids (Newcomer et al. 1994, in press ), which decrease hippocampal glucose transport (Homer et al. 1990) , can decrease memory performance in humans. Insulin stimulates glucose uptake in glial cells (Qarke et al. 1984; Dringen and Hamprecht 1992) and glucose transporter (GLUT1) mRNA is increased by insulin in both neurons and glia in primary culture (Werner et al. 1989) . Insulin can affect hippocampal firing rates in a dosedependent manner, with moderate levels increasing, and low or high levels inhibiting, firing (Palovcik et al. 1984) . have reported an inverted Ushaped dose-response relationship of plasma glucose to memory performance, analogous to the inverted U-shaped function for insulin and hippocampal firing. The preferential treatment effect on memory performance associated with the temporal lobe, versus other differentiated elements of cognitive performance, is consistent with relatively higher insulin receptor concentrations in this region, including the pyramidal cell layer and dentate gyms of the hippocampus (high density: regions CA1/2, moderate density: CA3/4) (Baskin et al. 1987; Unger et al. 1989; Schwartz et al. 1992) . These receptors are functionally relevant; intracerebroventricular injection of insulin increases entorhinal glucose utilization (Hoyer 1994 ) and streptozotocin-induced insulin receptor inactivation disrupts hippocampal glucose utilization (Plaschke and Hoyer 1993) . Extending evidence for insulin's effect on memory performance, this group has demonstrated increased memory performance in humans during insulin infusions with dextrose-maintained euglycemia (Craft et al. 1996Z») .
Glucose and insulin effects may also be mediated through effects on neurotransmitter systems involved in memory function. A relationship between brain acetylcholine (ACh) activity and brain glucose consumption is supported by reports that cholinergic treatments produce alterations in regional brain glucose uptake in rodents (Ray et al. 1992 ) and humans (Blin et al. 1994) , and that peripheral injections of glucose can attenuate scopolamine-induced memory deficits in mice (Messier et al. 1990 ). Glucose-induced increases in hippocampal ACh concentrations during treatment with scopolamine suggest a mechanism where increasing brain glucose, through its metabolism to the ACh precursor acetyl-coenzyme A, can increase ACh synthesis and release as well as memory performance (Durkin et al. 1992) . N-methyl-D-aspartate (NMDA) glutamate receptors may also be involved in glucose and insulin effects on memory performance. The activation of post-synaptic NMDA receptors is a requirement for the induction of an activity-dependent synaptic modification, long-term potentiation (LTP) (Bliss and Collingridge 1993; Collingridge and Bliss 1995) , that may underlie memory function (Morris et al. 1990; Davis et al. 1992; Doyere and Laroche 1992; Wilson and McNaughton 1993; Moser et al. 1994; Rison and Stanton 1995) . NMDA glutamate receptor hypofunction is hypothesized to be involved in the pathophysiology of schizophrenia (Olney 1988; Javitt and Zukin 1991; Olney and Farber 1995) and in the memory impairment associated with this disorder (Krystal et al. 1994; Malhotra et al. 1996; Newcomer et al. 1999) . Glucose availability can regulate the threshold for LTP induction in hippocampal slices (Izumi et al. 1993) , and insulin can potentiate NMDA receptor activity in rat hippocampus (Liu et al. 1995) . In vivo, investigators have reported that peripheral injections of glucose can attenuate memory deficits in mice induced by NPC 12626 (an NMDA glutamate receptor antagonist) (Walker and Gold 1992) .
Summary.
The results of this investigation provide preliminary support for the hypothesis that memory performance can be improved in patients with schizophrenia during an experimental increase in circulating glucose availability. The prominence and functional impact of memory and learning impairments in schizophrenia, and the current lack of specific biological treatments for cognitive impairments in this disorder, suggest the importance of further investigations into the effects of glucose and insulin on brain function.
